Clovis rallies on new CO-1686 data


Clovis Oncology (CLVS +0.5%) rises after updating investors on its EGFR inhibitor CO-1686.

CLVS says partial responses (RECIST) were observed in nine T790M positive patients (67% objective response rate). At ASCO, only four T790M positive patients were evaluable.

Eight of those patients (89%) "experienced tumor shrinkage greater than 10%." (PR)

From other sites
Comments (1)
  • Crash survivor87
    , contributor
    Comments (213) | Send Message
     
    A partial response is defined as a shrinkage of LD. The shrinkage
    has to be greater than 30%!!
    10% is just a stable disease.
    29 Oct 2013, 12:08 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs